BOTANIX PHARMACEUTICALS LTD — Board/Management Information 2021

Feb 28, 2021

==> picture [114 x 50] intentionally omitted <==

1 March 2021

Botanix Expands Management Team

• Botanix has expanded its management team with three new key hires in the US to drive its antimicrobial and dermatology programs

• New Chief Medical Officer, Vice President of Development and Head of Commercial join Botanix with deep expertise in drug development and particularly antimicrobials

• Botanix has terminated the consultancy of Executive Director Michael Thurn

• Recent positive data from BTX 1801 antimicrobial study underpins Botanix’s plans to develop its pipeline, accelerate development and scale up commercial capabilities

Philadelphia PA and Sydney Australia, 1 March 2021: Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”) is pleased to announce the expansion of its management team with three new key hires in the US to drive its antimicrobial and dermatology programs. Dr Clarence Young joins Botanix as Chief Medical Officer, Anthony Robinson joins as Vice President of Development and Lynda Berne joins as Head of Commercial.

Vince Ippolito, President and Executive Chairman, commented: “We are very pleased to welcome Clarence, Anthony and Lynda to the Botanix team at an exciting time when we are ramping up our clinical and commercial activities off the back of our recent successful BTX 1801 study. The depth and breadth of clinical and drug development experience that each of these executives bring to Botanix is exceptional and well suited to our near-term needs as we kick-off the BTX 1702 rosacea study and finalise planning for our next BTX 1801 study.”

Dr Young was recently Chief Medical Officer at Velicept Therapeutics and Senior Vice-President and Chief Medical Officer at Iroko Pharmaceuticals, where he provided clinical and medical leadership for three NDA filings and approvals. He also has held executive leadership positions for Novartis and one of its acquisitions, Protez Pharmaceuticals, where he served as Vice President, Drug Development and Chief Medical Officer. Dr. Young began his pharmaceutical career at GlaxoSmithKline, where he was Vice President and Global Head, Anti-Infectives Clinical Development. Dr. Young is a Fellow of the Infectious Diseases Society of America and served on the White House Working Group on Antimicrobial Resistance. He is a graduate of Williams College and Harvard Medical School and the author of numerous peer reviewed articles, reviews and scientific presentations.

Anthony Robinson was recently Vice President, Head of Clinical Operations, Program Management and Regulatory Affairs at Advicenne and previously held similar positions at Aquestive Therapeutics and Intrommune Therapeutics, and developed extensive expertise in drug development, clinical operations and regulatory affairs at Shire Pharmaceuticals (acquired by Takeda) and global contract research organisation, Covance. Anthony holds multiple qualifications including an MBA from Penn State University, a Master of Science from Drexel University and a Bachelor of Science from Cornell University.

==> picture [113 x 50] intentionally omitted <==

Lynda Berne is a founder of BAL Pharma Consulting, which provides commercial advisory services to biotech and specialty pharmaceutical companies. Lynda has held several senior and executive roles in the pharmaceutical industry encompassing broad commercial experience including 13 years at Bristol-Myers Squibb where she held the roles of Vice President, Infectious Disease Marketing, managing a $600m business unit and Vice President of Managed Health Care Sales. Other senior commercial positions held include General Manager of a $1bn cardiovascular and hospital business unit at Abbott International and Executive Director leading the $200m gastroenterology and nephrology Marketing business unit at Shire Pharmaceuticals. Lynda holds an MBA from Northwestern University (Kellogg Graduate School of Management), a Master of Science from DePaul University and a Bachelor of Science from Indiana University.

Lastly, Botanix has terminated the consultancy agreement with Company Executive Director Dr Michael Thurn and he has resigned from the Board of Botanix effective 26 February 2021.

The Company is well funded to progress both its dermatology and antimicrobial platforms, with the planned BTX 1702 rosacea Phase 1b study on track to commence in 1H CY2021, and its antimicrobial platform planned to expand following the recent completion of its BTX 1801 Phase 2a nasal decolonisation study. The Company also continues to assess complementary opportunities and partnerships for products that can be rapidly brought to market and these changes in management for Botanix provide significant additional capability and experience to accelerate both existing the potential opportunities in dermatology and antimicrobials.

Release authorised by

Vince Ippolito

President and Executive Chairman

==> picture [113 x 50] intentionally omitted <==

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage synthetic cannabinoid company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has two separate cannabinoid development platforms, dermatology and antimicrobial products, both of which leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex) for direct skin delivery of active pharmaceuticals in all skin diseases.

The Company is developing a pipeline of product candidates that leverages the antimicrobial properties of cannabinoids with recent positive data from its BTX 1801 Phase 2a antimicrobial study. For the dermatology platform, the Company is well progressed towards initiating its Phase 1b rosacea study in 1H CY2021 and following a successful meeting with the FDA, the Company has confirmed a drug development plan for the BTX 1503 acne program to support registration.

To learn more please visit: https://www.botanixpharma.com/

For more information, please contact:

General enquiries Investor enquiries Media enquiries Corporate Communications Joel Seah Haley Chartres Botanix Pharmaceuticals Vesparum Capital H^CK P: +61 8 6555 2945 P: +61 3 8582 4800 P: +61 423 139 163 investors@botanixpharma.com botanixpharma@vesparum.com haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate, ”expect,” “intend,” “may,” “plan,” “predict,” “project,” “target, ”potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.